XML 25 R12.htm IDEA: XBRL DOCUMENT
v3.22.0.1

GOODWILL AND INTANGIBLE ASSETS | 12 Months Ended
--- | ---
Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract] |
GOODWILL AND INTANGIBLE ASSETS | GOODWILL AND INTANGIBLE ASSETS The change in the carrying value of Goodwill was as follows:
| December 31,
| 2021 |  | 2020
Beginning balance | $ | 196,199 |  |  | $ | 197,039 |
Disposition | — |  |  | (840) |
Ending carrying value | $ | 196,199 |  |  | $ | 196,199 |
In January 2020, the Company completed the sale of worldwide rights to Firdapse, the Company's commercial product for the treatment of Lambert-Eaton myasthenic syndrome, to a third party in exchange for a one-time cash payment of $67.2 million plus residual royalties. Under the terms of the agreement, the Company agreed to provide certain transition services to the third-party purchaser, such as customer sales and support, for up to 12 months after the closing of the transaction. During the first quarter of 2020, the Company recognized a before-tax net gain of $59.5 million related to the sale of the Firdapse intellectual property (IP) and existing inventory. As a result of the sale of Firdapse, in the first quarter of 2020 the Company recognized a $0.8 million reduction to Goodwill and disposed of $32.2 million in intangible assets, including related accumulated amortization of $31.6 million. The Company performed its annual assessment for goodwill impairment for the year ended December 31, 2021 and no goodwill impairment charges were recorded. Intangible Assets, Net consisted of the following:
| December 31,
| 2021 |  | 2020
Finite-lived intangible assets | $ | 677,350 |  |  | $ | 644,087 |
Accumulated amortization | (288,698) |  |  | (226,816) |
Net carrying value | $ | 388,652 |  |  | $ | 417,271 |
During the fourth quarter of 2021 the Company capitalized a $6.0 million Voxzogo regulatory approval milestone payment as a finite-lived intangible asset in the Company's Consolidated Balance Sheet following the FDA's approval of Voxzogo. The following table summarizes the carrying value and estimated remaining life of the Company’s finite-lived intangible assets as of December 31, 2021:
| Net Balance |  | Average Remaining Life
Acquired intellectual property | $ | 295,299 |  |  | 6.0 years
Technology transfer | 74,055 |  |  | Not applicable (1)
Repurchased royalty rights | 12,937 |  |  | 1.9 years
License payments | 6,203 |  |  | 8.7 years
Other | 158 |  |  | 1.4 years
Total | $ | 388,652 |  |  |
(1)The technology transfer intangible asset has not yet been placed into service. As of December 31, 2021, the estimated future amortization expense associated with the Company’s finite-lived intangible assets, exclusive of the technology transfer asset that has not been placed into service, was as follows:
Fiscal Year |  | Amount
2022 |  | $ | 62,606 |
2023 |  | 61,978 |
2024 |  | 55,702 |
2025 |  | 36,426 |
2026 |  | 36,426 |
Thereafter |  | 61,459 |
|  | $ | 314,597 |
In 2019, the Company received $25.0 million due to the achievement by a third party of development and regulatory milestones and commercial sales milestones related to a previously sold intangible asset, which the Company recorded as a Gain on Sale of Nonfinancial Assets in the Consolidated Statements of Operations.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for all or part of the information related to intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -URI http://asc.fasb.org/topic&trid=2144416 + Details
Name: | us-gaap_IntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration